Treatment of relapsed Wilms tumors: lessons learned

References

• Green DM, Breslow NE, Beckwith JB et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. J. Clin. Oncol.16, 237–245 (1998).
   PubMed Web of Science ®Google Scholar
• de Kraker J, Graf N, van Tinteren H et al. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms’ tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet364, 1229–1235 (2004).
   PubMed Web of Science ®Google Scholar
• Tournade MF, Com-Nougué C, de Kraker J et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms’ tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms’ Tumor Trial and Study. J. Clin. Oncol.19, 488–500 (2001).
   PubMed Web of Science ®Google Scholar
• Neville HL, Ritchey ML. Wilms’ tumor. Overview of the National Wilms’ Tumor Study Group results. Urol. Clin. North Am.27, 435–442 (2000).
   PubMed Web of Science ®Google Scholar
• Graf N, Tournade MF, de Kraker J. The role of preoperative chemotherapy in the management of Wilms’s tumor. Urol. Clin. North Am.27, 443–454 (2000).
   PubMed Web of Science ®Google Scholar
• Green DM. The treatment of stages I–IV favourable histology Wilms’ tumor. J. Clin. Oncol.22, 1366–1372 (2004).
   PubMed Web of Science ®Google Scholar
• Mitchell C, Pritchard-Jones K, Shannon R et al. Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms’ tumour: results of a randomised trial (UKW3) by the UK Children’s Cancer Study Group. Eur. J. Cancer42, 2554–2262 (2006).
   PubMed Web of Science ®Google Scholar
• Kalapurakal JA, Dome JS, Pearlman EJ et al. Management of Wilms’ tumour: current practice and future goals. Lancet Oncol.5, 37 (2004).
   PubMed Web of Science ®Google Scholar
• Miser JS, Tournade MF. The management of relapsed Wilms tumor. Hematol. Oncol. Clin. North Am.9, 1287–1302 (1995).
   Google Scholar
• Garaventa A, Hartmann O, Bernard JL et al. Autologous bone marrow transplantation for pediatric Wilms’ tumour: the experience of the European Bone Marrow Transplantation Solid Tumour Registry. Med. Pediatr. Oncol.22, 11–14 (1994).
   PubMedGoogle Scholar
• Dome JS, Liu T, Krasin M et al. Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children’s Research Hospital. J. Ped. Hematol. Oncol.24, 192–198 (2002).
   PubMed Web of Science ®Google Scholar
• Grundy P, Breslow N, Green DM et al. Prognostic factors for children with recurrent Wilms’ tumor: results from the second and third National Wilms’ Tumor Study. J. Clin. Oncol.5, 638–647 (1989).
   Google Scholar
• van den Heuvel-Eibrink MM, Graf N, Pein F et al. Intracranial relapse in Wilms tumor patients. Pediatr. Blood Cancer43, 737–741 (2004).
   PubMedGoogle Scholar
• Lowis SP, Foot A, Gerrard MP et al. Central nervous system metastasis in Wilms tumor: a review of three consecutive United Kingdom trials. Cancer83, 2023–2029 (1998).
   Google Scholar
• Spreafico F, Pritchard-Jones K, Bergeron C, de Kraker J, Dallorso S, Graf N. Value and difficulties of a common European strategy for recurrent Wilms’ tumor. Expert Rev. Anticancer Ther.9(6), 693–696 (2009).
   PubMed Web of Science ®Google Scholar
• Tournade MF, Lemerle J, Brunat-Mentigny M et al. Ifosfamide is an active drug in Wilms’ tumor: a Phase II study conducted by the French Society of Pediatric Oncology. J. Clin. Oncol.6, 793–796 (1988).
   PubMedGoogle Scholar
• Pein F, Pinkerton R, Tournade MF et al. Etoposide in relapsed Wilms’ tumor: a Phase II study by the French Society of Pediatric Oncology. J. Clin. Oncol.11, 1478–1481 (1993).
   PubMed Web of Science ®Google Scholar
• De Camargo B, Melarango R, Saba e Silva N et al. Phase II study of carboplatin as a single drug for relapsed Wilms’ tumor: experience of the Brazilian Wilms’ Tumor Study Group. Med. Ped. Oncol.22, 258–260 (1994).
   PubMedGoogle Scholar
• Pein F, Tournade MF, Zucker JM et al. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms’ tumor – a Phase II study by the French Society of Pediatric Oncology. J. Clin. Oncol.12, 931–936 (1994).
   PubMed Web of Science ®Google Scholar
• Pinkerton CR, Groot-Loonen JJ, Morris-Jones PH, Pritchard J. Response rates in relapsed Wilms’ tumor. A need for new effective agents. Cancer67, 567–571 (1991).
   Google Scholar
• Metzger ML, Stewart CF, Freeman BB 3rd et al. Topotecan is active against Wilms’ tumor: results of a multi-institutional Phase II study. J. Clin. Oncol.21, 3130–3136 (2007).
   Google Scholar
• Pein F, Michon J, Valteau-Couanet D et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms’ tumor: a French Society of Pediatric Oncology study. J. Clin. Oncol.16, 3295–3301 (1998).
   PubMed Web of Science ®Google Scholar
• Kremens B, Gruhn B, Klingebiel T et al. High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplant.30, 893–898 (2002).
   PubMed Web of Science ®Google Scholar
• Abu-Ghosh AM, Krailo MD, Goldman SC et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms’ tumor: a Children’s Cancer group report. Ann. Oncol.13, 460–469 (2002).
   PubMed Web of Science ®Google Scholar
• Malogolowkin M, Cotton CA, Green DM et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Ped. Blood Cancer50, 236–241 (2008).
   PubMedGoogle Scholar
• Spreafico F, Bisogno G, Collini P et al. Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem-cell support: experience by the Italian Association of Pediatric Hematology and Oncology. Ped. Blood Cancer51, 23–28 (2008).
   PubMed Web of Science ®Google Scholar
• Green DM, Cotton CA, Malogolowkin M et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. Pediatr. Blood Cancer48, 493–499 (2007).
   PubMedGoogle Scholar
• Pein F, Rey A, de Kraker J et al. Multivariate analysis of adverse prognostic factors (APF) in children with recurrent (Rec) Wilms’ tumor (WT) after initial treatment according to SIOP-6 or SIOP-9 strategies. Med. Pediatr. Oncol.33, 170 (1999) (Abstract 111).
   Google Scholar
• Vujanic GM, Sandstedt B, Harms D et al. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med. Pediatr. Oncol.38, 79–82 (2002).
   PubMedGoogle Scholar
• Reinhard H, Schmidt A, Furtwängler R et al. Outcome of relapses of nephroblastoma in patients registered in the SIOP/GPOH trials and studies. Oncol. Rep.20, 463–467 (2008).
   PubMed Web of Science ®Google Scholar
• Hale J, Hobson R, Moroz V, Sartori P. Results of UK Children’s Cancer and Leukemia Group (CCLG) protocol for relapsed Wilms tumor (UKWR): unified relapse strategy improves outcome. Proceeding of the 40th Meeting of International Society of Paediatric Oncology. 62 (2008) (Abstract O154).
   Google Scholar
• Dome JS, Cotton CA, Pearlman EJ et al. Treatment of anaplastic histology Wilms’ tumor: results from the fifth National Wilms’ Tumor Study. J. Clin. Oncol.24, 2352–2358 (2006).
   PubMedGoogle Scholar
• Daw NC, Gregornik D, Rodman J et al. Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumor. Eur. J. Cancer45, 99–106 (2009).
   Google Scholar
• Malogolowkin MH, Casak SJ, Feusner J et al. Carboplatin and etoposide alternating with ifosfamide and doxorubicin for the treatment of children with recurrent Wilms’ tumors. Proceedings of ASCO.13, 424 (1994) (Abstract 1453).
   Google Scholar
• Campbell AD, Cohn SL, Reynolds M et al. Treatment of relapsed Wilms’ Tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children’s Memorial Hospital. J. Clin. Oncol.22, 2885–2890 (2004).
   PubMed Web of Science ®Google Scholar
• Tannous R, Giller R, Holmes E et al. Intensive therapy for high risk (HR) relapsed Wilm’s tumor (WT). A CCG-4921/POG-9445 Study Report. Proceedings of ASCO.19, 588a (2000) (Abstract 2315).
   Google Scholar
• Nitschke R, Parkhurst J, Sullivan J et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group Phase II study. J. Pediatr. Hematol. Oncol.20, 315–318 (1998).
   PubMed Web of Science ®Google Scholar
• Dome JS, Neale G, Hill DA et al. Anti-tumor activity of topotecan against Wilms tumor: translation of a xenograft model to Phase II study. Pediatr. Blood Cancer45, 432–433 (2005).
   Google Scholar
• Tubergen DG, Stewart CF, Pratt CB et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a Pediatric Oncology Group study. J. Pediatr. Hematol. Oncol.18, 352–361 (1996).
   PubMed Web of Science ®Google Scholar
• Metzger ML, Stewart CF, Freeman BB 3rd et al. Topotecan is active against Wilms’ tumor: results of a multi-institutional Phase II study. J. Clin. Oncol.21, 3130–3136 (2007).
   Google Scholar
• Perlman EJ. Pediatric renal tumors: practical updates for the pathologists. Pediatr. Dev. Pathol.8, 320–338 (2005).
   PubMedGoogle Scholar
• Green DM, Beckwith BJ, Breslow NE et al. Treatment of children with stages II to IV anaplastic Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. J. Clin. Oncol.12, 2126–2131 (1994).
   PubMed Web of Science ®Google Scholar
• Italiano A, Sirvent N, Michiels JF et al. Tumour response to paclitaxel in an adult with relapsed nephroblastoma. Lancet Oncol.6, 252–253 (2005).
   Google Scholar
• Ramanathan RK, Rubin JT, Ohori NP, Belani CP. Dramatic response of adult Wilms’ tumour to paclitaxel and cisplatin. Med. Pediatr. Oncol.34, 296–298 (2000).
   Google Scholar
• Spunt SL, Freeman BB 3rd, Billups CA et al. Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors. J. Clin. Oncol.25, 2274 (2007).
   PubMed Web of Science ®Google Scholar
• McGregor LM, Spunt SL, Santana VL et al. Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors. Cancer115, 655 (2009).
   Google Scholar
• Ghanem MA, van Steenbrugge GJ, Sudaryo MK et al. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J. Clin. Pathol.56, 107–113 (2003).
   PubMed Web of Science ®Google Scholar
• Benesch M, Wildenberg M, Sauseng W et al. Compassionate use of bevacizumab (Avastin®) in children and young adults with refractory or recurrent solid tumors. Ann. Oncol.19, 807–813 (2008).
   PubMed Web of Science ®Google Scholar
• Adamson PC, Matthay KK, O’Brein M, Reaman GH, Sato JK, Balis FM. A Phase 2 trial of all-trans-retinoic acid in combination with interferon-α2A in children with recurrent neuroblastoma or Wilms tumor: a Pediatric Oncology Branch, NCI and Children’s Oncology Group study. Pediatr. Blood Cancer49, 661–665 (2007).
   PubMed Web of Science ®Google Scholar
• Zirn B, Hartmann O, Samans B et al. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. Int. J. Cancer118, 1954–1962 (2006).
   Google Scholar
• Zirn B, Samans B, Spangenberg C, Graf N, Eilers M, Gessler M. All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene24, 5346–5251 (2005).
   Google Scholar
• Witt O, Hämmerling S, Stockklausner C et al. 13-cis retinoic acid treatment of a patient with chemotherapy refractory nephroblastomatosis. J. Pediatr. Hematol. Oncol.31, 296–299 (2009).
   Google Scholar
• Green DM, Breslow NE, Ii Y et al. The role of surgical excision in the management of relapsed Wilms’ tumor patients with pulmonary metastases: a report from the National Wilms’ Tumor Study. J. Pediatr. Surg.26, 728–733 (1991).
   Google Scholar
• Fuchs J, Szavay P, Luithle T, Furtwängler R, Graf N. Surgical implications for liver metastases in nephroblastoma – data from the SIOP/GPOH study. Surg. Oncol.17, 33–40 (2008).
   Google Scholar
• Bardeesy N, Beckwith JB, Pelletier J. Clonal expansion and attenuated apoptosis in Wilms’ tumors are associated with p53 gene mutations. Cancer Res.55, 215–219 (1995).
   PubMed Web of Science ®Google Scholar
• Bardeesy N, Falkoff D, Petruzzi MJ et al. Anaplastic Wilms’ tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat. Genet.7, 91–97 (1994).
   PubMed Web of Science ®Google Scholar
• Stock C, Ambros IM, Lion T et al. Genetic changes of two Wilms’ tumors with anaplasia and a review of the literature suggesting a marker profile for therapy resistance. Cancer Genet. Cytogenet.135, 128–138 (2002).
   PubMedGoogle Scholar
• Natrajan R, Little SE, Sodha N et al. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms’ tumour. J. Pathol.211, 52–59 (2007).
   PubMed Web of Science ®Google Scholar
• Huang CC, Gadd S, Breslow N et al. Predicting relapse in favorable histology Wilms tumor using gene expression analysis: a report from the Renal Tumor Committee of the Children’s Oncology Group. Clin. Cancer Res.15, 1770–1778 (2009).
   PubMed Web of Science ®Google Scholar
• Grundy PE, Breslow NE, Li S et al. Loss of heterozygosity for chromosome 1p and 16q is an adverse prognostic factor in favourable histology Wilms tumor: a report from the National Wilms Tumor Study Group. J. Clin. Oncol.23, 7312–7321 (2005).
   PubMed Web of Science ®Google Scholar